INmune BioINMB
Market Cap: $116M
About: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Employees: 17
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
55% more call options, than puts
Call options by funds: $765K | Put options by funds: $492K
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
25% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 12
24% more capital invested
Capital invested by funds: $32.5M [Q1] → $40.3M (+$7.78M) [Q2]
10% more funds holding
Funds holding: 51 [Q1] → 56 (+5) [Q2]
7.73% more ownership
Funds ownership: 15.35% [Q1] → 23.09% (+7.73%) [Q2]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Scotiabank George Farmer 40% 1-year accuracy 6 / 15 met price target | 274%upside $22 | Sector Outperform Initiated | 22 Aug 2024 |